WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, February 23, 2004

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L24	L22 same l12	10
☐	L23	L22 same monoclonal	3
☐	L22	H36 or (H36 adj D2 adj B7)	334
	DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L21	5506134 .pn.	1
☐	L20	L19 same factor	14
☐	L19	L18 same human	611
☐	L18	L17 same murine	634
☐	L17	L16 same cdr$	1527
☐	L16	humaniz$ with antibod$	5464
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L15	humaniz$ with antibod$	14865
☐	L14	L13 same (fx or fix or (factor x) or (factor IX))	27
☐	L13	(anti or antibod$) adj L12	186
☐	L12	tf or (tissue factor)	94953
☐	L11	luepschen-lawrence.in.	5
☐	L10	nieves-esperanza.in.	0
☐	L9	jiao-'jin-an' .in.	27
☐	L8	wong-hing.in.	50
	DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L7	5216132.pn.	1
☐	L6	5552300.pn.	1
☐	L5	5589173.pn.	1
☐	L4	6274142.pn.	1
☐	L3	5437864.pn.	1
☐	L2	5986065.pn.	1
☐	L1	5223427.pn.	1

END OF SEARCH HISTORY

h e b b cg b chh e h e f c e h

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, February 23, 2004

Hide?	Set Name	Query	Hit Count
	DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L7	5216132.pn.	1
☐	L6	5552300.pn.	1
☐	L5	5589173.pn.	1
☐	L4	6274142.pn.	1
☐	L3	5437864.pn.	1
☐	L2	5986065.pn.	1
☐	L1	5223427.pn.	1

END OF SEARCH HISTORY

Deposit statement From 09/293,854

> [I]t is incumbent upon the Patent Office, whenever a rejection on this basis is made, to explain why it doubts the truth or accuracy of any statement in a supporting disclosure and to back up assertions of its own with acceptable evidence or reasoning which is inconsistent with the contested statement. Otherwise, there would be no need for the applicant to go to the trouble and expense of supporting his presumptively accurate disclosure.

Regarding the requested deposit, Applicants submit that a hybridoma culture producing the H36.D2.B7 antibody was deposited with the American Type Culture Collection (ATCC) at 10801 University Boulevard, Mansassas, VA 20110-2209. The hydridoma culture was deposited with the ATCC on January 8, 1997, and was assigned Accession Number ATCC HB-12255 (see page 15, lines 16-20 of the specification. As mentioned above, the ATCC address as set forth on page 15 of the application has been updated as requested at page 4 of the Office Action.

Additionally, the undersigned attorney also avers on behalf of Applicants that the deposit was made under the terms of the Budapest Treat and that:

a) during the pendency of the application, access to the deposit will be afforded to one determined by the Commissioner to be entitled thereto;

b) all restrictions imposed by the depositer on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent;

c) the deposit will be maintained for a term of at least thirty (30) years and at least five (5) years after the most recent request for the furnishing of a sample of the deposited materials;

d) a viability statement in accordance with 37 CFR 1.807 will be provided if requested; and

e) the deposit will be replaced should it become necessary due to inviability,

E

Claims 40, 42, and 47 were rejected under [illegible] 5,223,427) or Fiore (*Blood* article) in view of Morrison (*Ann. Rev. Immunol.* article).

Claims 45 and 46 were rejected under 35 U.S.C. 103 over Edgington (U.S. Patent 5,223,427) or Fiore (*Blood* article) in view of Morrison (*Ann. Rev. Immunol.* article), and further in view of Groves (*Hybridoma* article).

For the sake of brevity, the two rejections are addressed in combination. Such a combined response is considered appropriate because, *inter alia*, both rejections rely on the Edgington document as a primary citation. The rejections are each traversed.

As discussed during the interview, antibodies disclosed in the present application can effectively bind human tissue factor and inhibit Factor X binding to the antibody-complexed human tissue factor.

In this regard, attention is directed to the examples of the application, which shows preferred exemplified antibodies can complex with human tissue factor and inhibit binding of Factor X, while having much less effect on binding of Factor VIIa. These results are summarized at Figures 3 and 4.

More particularly, Example 3 of the application evaluates the capacity of selected antibodies to block tissue factor-mediated activation of Factor X to Factor Xa. Example 4 of the application evaluates the capacity of the tested antibodies to interfere with the interaction (binding) between TF and Factor VIIa.